关于济民可信集团<\/b><\/p> \n
济民可信集团是中国知名大型现代制药集团之一，致力于为患者提供高质量的药品和创新医药解决方案，连续多年蝉联中国制药工业百强前十。济民可信研发中心落户于上海张江科学城，现有研发人员超过500人，已完成生物大分子、化学小分子、创新技术药物等技术平台的搭建，致力于在肾病、肿瘤、心脑血管、呼吸系统、抗感染、儿科、疼痛等治疗领域取得突破性成果。<\/p> \n
更多信息请登陆：www.jemincare.com<\/a> <\/p> \n或联系：PR@jemincare.com<\/a> <\/p> \n备注：<\/b><\/p> \n \n Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody: mechanisms for the high infectivity, immune evasion and antibody drug discovery<\/li> \n<\/ol> \n \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
或联系：PR@jemincare.com<\/a> <\/p> \n备注：<\/b><\/p> \n \n Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody: mechanisms for the high infectivity, immune evasion and antibody drug discovery<\/li> \n<\/ol> \n \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
备注：<\/b><\/p> \n \n Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody: mechanisms for the high infectivity, immune evasion and antibody drug discovery<\/li> \n<\/ol> \n \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();